Evaluating the Efficacy of Levonorgestrelreleasing Intrauterine System in the Management of Menorrhagia: A Prospective Cohort Study

Read full text Summarise with VIRAT
Authors: Saranya Manivannan, Hemaswapnika Devireddy, Jetty Karthik, Prithi Dinesh Kumar, Navin Puttum
Cited by: 0
References: 21

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Introduction: Although heavy menstrual bleeding rarely poses a life-threatening risk, it significantly disrupts women’s lives, causing discomfort and inconvenience. The term “menorrhagia” encompasses the notion of heavy menstrual bleeding. Despite effective conservative surgical solutions, a substantial number of women still choose hysterectomy. Preserving patient autonomy in selecting treatments for menstrual disorders is essential for sustainable care. The Levonorgestrel-releasing Intrauterine System (LNG-IUS), infused with progesterone, emerges as a promising surgical alternative due to its potential to decrease blood loss during menstruation. Aim: To evaluate the effectiveness of LNG-IUS in controlling heavy menstrual bleeding in women with menorrhagia. Materials and Methods: The present prospective cohort study was conducted in the Department of Obstetrics and Gynaecology at Vinayaka Mission’s Kirupananda Variyar Medical College and Hospital, Salem, Tamil Nadu, India, for 1 year. Fifty women experiencing heavy menstrual bleeding (>80 mL per cycle) underwent LNG-IUS treatment. Menstrual blood loss was assessed using modified imaging assessment of blood loss Pictorial Blood Loss Assessment Chart (PBAC) at three, six, and nine months postinsertion. Efficacy markers encompassed the observation of increased haemoglobin (Hb) levels, the reduction of PBAC scores both before and after LNG-IUS insertion. Further evaluation encompassed parameters such as the regularity of menstrual cycles and the monitoring of adverse effects after LNG-IUS implantation. Continuous variables were expressed in terms of means, standard deviations (SD), while categorical variables were expressed in terms of frequency and percentage. Analysis of Variance (ANOVA) test was used. A p-value of less than 0.05 was considered statistically significant. Results: The mean age of the subjects was 35.16 years. The analysis revealed a significant reduction in menstrual blood loss, reflected by a decrease in PBAC score from an average of 198.86 before treatment to 8.78 after nine months of supplementation. Furthermore, haemoglobin percentage (Hb%) improved notably, increasing from an initial average of 9.1% to 10.6% after nine months. About 32% of patients achieved amenorrhoea after nine months. Spontaneous device expulsion occurred in one patient during the sixth month, while another requested removal in the ninth month. Conclusion: As a non-surgical avenue for menorrhagia, LNG-IUS offers a practical alternative. Positive feedback and sustained adherence highlight its potential as a substitute for managing heavy menstrual bleeding.

Fields of Study & Subjects

Menstrual Health and Disorders Reproductive Health and Contraception Uterine Myomas and Treatments

Publication details

Journal / source
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH
Publication date
21 March 2026
Language
EN